Conflict of interest: Nothing to declare.
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program†
Article first published online: 21 SEP 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 5, pages 791–798, May 2013
How to Cite
Reynolds, C. P., Kang, M. H., Carol, H., Lock, R., Gorlick, R., Kolb, E. A., Kurmasheva, R. T., Keir, S. T., Maris, J. M., Billups, C. A., Houghton, P. J. and Smith, M. A. (2013), Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr. Blood Cancer, 60: 791–798. doi: 10.1002/pbc.24301
- Issue published online: 14 MAR 2013
- Article first published online: 21 SEP 2012
- Manuscript Accepted: 6 AUG 2012
- Manuscript Received: 19 JUN 2012
- National Cancer Institute. Grant Numbers: NO1-CM-42216, CA21765, CA108786
- Exelixis Inc., San Francisco, CA. Grant Number: SAR245408
Additional Supporting Information may be found in the online version of this article.
|pbc_24301_sm_SuppResDef.doc||77K||Supplemental Response Definitions.|
|pbc_24301_sm_SuppTab1.doc||306K||Supplemental Table 1. Efficacy of SAR245408 against PPTP Xenograft Models.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.